Tyagi et al
Understanding semaglutide plateau management becomes critical at this stage, as the body can develop some tolerance to GLP-1 receptor activation over time
1, 2233.CrossRefGoogle ScholarPubMed Brunetti, L, Orlando, G, Recinella, L, Leone, S, Ferrante, C, Chiavaroli, A, Lazzarin, F and Vacca, M (2008) Glucagon-like peptide 1 (7-36) amide (GLP-1) and exendin-4 stimulate serotonin release in rat hypothalamus
Tang, H., Zhang, B., Lu, Y., Donahoo, W
Then, over 30 years ago, clinicians began to see the value of incretin-based therapy for T2DM, which led to a plethora of clinical trials confirming that GLP-1 receptor agonists are effective in the management of T2DM
Their glucose-dependent mechanism of action helps reduce blood sugar without driving it dangerously low